Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

General Mills Recalls Flour After E. coli Outbreak

XTALKS VITALS NEWS

Flour

Consumers are being warned by both the FDA and the CDC not to consume any raw products containing flour, including cookie dough and cake batter.

Tweetables from this article:

Tweet: General Mills recalls more batches of #flour after E. coli outbreak http://ctt.ec/9J32Y+General Mills recalls more batches of flour after E. coli outbreak.

Tweet: CDC: 42 individuals across 21 states have been become ill as a result of contaminated flour http://ctt.ec/JnNmB+CDC: 42 individuals across 21 states have been become ill as a result of contaminated flour.

Share this!

July 5, 2016 | by Sarah Massey, M.Sc.

General Mills is recalling more batches of its flour after a multi-state outbreak of E. coli was linked to some of its products. The list of recalled products includes those branded as Gold Medal flour, Wondra flour and Signature Kitchens flour.

The newest update on the recall now includes batches prepared in the fall of 2015, which some consumers may still have in their pantry. The catalyst for the recall expansion was a new case of foodborne illness which “appears to have stemmed from the consumption of raw dough or batter linked to flour produced last fall.”

According to the Centers for Disease Control and Prevention (CDC), 42 individuals across 21 states have been become ill as a result of exposure to the contaminated flour. The flour has been found to contain Shiga toxin-producing E. coli (STEC) O121, and 11 people have been hospitalized due to the infection.



A type of kidney failure known as hemolytic uremic syndrome has so far not been developed in any of the affected individuals, and no illness-related deaths have been reported. Four new cases of the illness were identified in the month of June alone, and the STEC O121 bacterial strain has been isolated from flour samples collected from the homes of two ill people.

“In late June 2016, the [U.S. Food and Drug Administration (FDA)] isolated STEC O121 from samples of General Mills flour collected from the homes of ill people in Arizona and Oklahoma,” said the CDC. “The flour collected in Oklahoma was not included in the initial General Mills recall. In response to these laboratory findings, on July 1, 2016, General Mills expanded the recall to include additional lots of flour under the same brands from the initial recall.”

Consumers are being warned by both the FDA and the CDC not to consume any raw products containing flour, including cookie dough and cake batter. Baking, frying and boiling are all effective methods to kill the STEC O121 pathogen, however the affected batches of flour should be discarded.


Keywords: FDA, Recall, Foodborne Illness


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Use of Testosterone Treatments Boosted by DTC Ad Campaigns

March 24, 2017 - Those with a stake in the pharmaceutical industry often question the effectiveness of direct-to-consumer (DTC) advertising, and whether it truly influences consumers to talk to their doctors about medical conditions and perhaps even ask for drugs by name.

Featured In: Pharmaceutical Marketing News


FDA Approves New Drug for Parkinson’s Disease

March 23, 2017 - Newron Pharmaceuticals’ Xadago (safinamide) has been approved by the US Food and Drug Administration (FDA) as an add-on medication for patients with Parkinson’s disease.

Featured In: Clinical Trials News, Life Science News, Pharmaceutical News


Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.